drugset / Trial / NCT04156100
A Study in Subjects With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 as a single-agent and in combination with balstilimab, as well as to assess the maximum tolerated dose and determine the RP2D of AGEN1223 as a single-agent and in combination with balstilimab in subjects with advanced solid tumors.
Timeline
- Start
- 2019-12-10
- Primary completion
- 2021-04-08
- Completion
- 2021-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGEN1223 | Unknown | — | — |
| Subject | Balstilimab | Monoclonal antibody | — | — |